資源描述：
《疏肝止痛方治療氣滯血瘀型原發(fā)性痛經(jīng)的臨床觀察論文》由會員上傳分享，免費在線閱讀，更多相關(guān)內(nèi)容在學(xué)術(shù)論文-天天文庫。
1、ClinicalResearchonTreatingtheQiandBloodstasisPrimaryDysmenorrheawiththeShuGanZhiTongDecoctionSpeciality：GynecologyofTCMAuthor：ZhuwenyanTutor：ProfessorLvMeiAbstractObjective:ToobservetheclinicaleffectionoftreatingthestagnationofqiandbloodstasisPrimaryDysmenorrheawithth
2、eShuGanZhiTong(SGZT)Decoctionandexplorethefunctionmechanismofit.Methods:78patientsweredividedintothreegroupsrandomly:thetreatmentgroupⅠ(26cases,treatedwithSGZTforthreemonths,sevendaysbytheformerfromtheoral),thetreatmentgroupⅡ(26cases,treatedwithSGZTforthreemonths,four
3、teendaysbytheformerfromtheoral)andthecontrolgroup(26cases,treatedwithDanErFuKangDFEforthreemonths).Thechangesofclinicalsymptomsandsigns,uterinearterybloodflowandthebloodrheologywereobservedbeforeandaftertreatment.Result:Theimprovementofsyndromeofthetwotreatmentgroupsw
4、eresignificantlyabovethecontrolgroup.therewasnonotabledifferenceinthetotalcurativeeffectbetweentreatmentgroupⅠandthetreatmentgroupⅡ.Aftertreatment,uterinearterybloodflowandthebloodrheologywasdecreasedsignificantly(P﹤0.05).Conclusions:SGZTDecoctionisaneffectiverecipein
5、treatingPrimaryDysmenorrhea,theeffectcanbereducepelvicbloodflowresistance,amelioratingthebloodrheology.Longcourseofmedicationisbetterthanashortcourseoftreatmentmedication.KeywordsShuGanZhiTongDecoction;stagnationofqiandbloodstasis;PrimaryDysmenorrhea;clinicalcurative
6、effect目錄引言...............................................................................................................................1臨床研究............................................................................................................................
7、...2一、臨床資料.......................................................................................................................2（一）病例來源...................................................................................................................2（二）診斷標準........
8、...........................................................................................................2（三）病例選擇標準.......
